Misplaced Pages

Technetium (Tc) votumumab (trade name HumaSPECT) is a human monoclonal antibody labelled with the radionuclide technetium-99m. It was developed for the detection of colorectal tumors, but has never been marketed.

The target of votumumab is CTAA16.88, a complex of cytokeratin polypeptides in the molecular weight range of 35 to 43 kDa, which is expressed in colorectal tumors.

References

1. "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (1). 1999.
2. Hendriks BS, Gaddy DF (2017). "Radiolabeled Antibody-Based Imaging in Clinical Oncology". In Olivier Jr KJ, Hurvitz SA (eds.). Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer. Hoboken, New Jersey: John Wiley & Sons. p. 441. ISBN 978-1-119-06084-0.
3. "Public Statement on HumaSPECT" (PDF). European Medicines Agency (EMA_. 23 February 2004. Archived from the original (PDF) on 2007-06-10. Non-renewal of the marketing authorisation in the European Union
4. "Summary of Product Characteristics for HumaSPECT" (PDF). European Medicines Agency (EMA).

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This nuclear medicine article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Radiopharmaceuticals
• Technetium-99m
• Abandoned drugs
• Technetium compounds
• Antibody-drug conjugates
• Monoclonal antibody stubs
• Nuclear medicine stubs